Table 4.
Characteristics of the included study populations
| PROM | References | Population | Disease | Instrument administration | Measurement properties | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| n | Agea | Genderb | Stage | Treatment | Setting | Country (language) | Response rate (%) | |||
| TESS | Kask et al. [90] | 136 | 65.6 (14.4) | 66 (48.5) | Local STS (lower extremity) | Surgery | Clinical | Finland (Finnish) | 70 | Structural validity, internal consistency, measurement invariance, reliability and hypotheses testing for construct validity |
| Ketola et al. [91] | 55 | 62.8 (14.6) | 27 (49.1) | Local STS (upper extremity) | Limb-sparing surgery | Clinical | Finland (Finnish) | 85 | Internal consistency, measurement invariance and hypotheses testing for construct validity | |
| QuickDASH | Ketola et al. [91] | 55 | 62.8 (14.6) | 27 (49.1) | Local STS (upper extremity) | Limb-sparing surgery | Clinical | Finland (Finnish) | 85 | Internal consistency, measurement invariance and hypotheses testing for construct validity |
| EORTC-QLQ-C30 | Gough et al. [54] | 27; 14c | 52.2 (14) | 21 (32) | Locally advanced, inoperable or metastatic STS | Palliative chemotherapy or under surveillance after first-line palliative chemotherapy having responded favorably | Clinical | United Kingdom (English) | 84 | Content validity (the relevance of the PROM items) |
PROM patient-reported outcome measure, STS soft-tissue sarcoma
aMean (SD) or median [IQR]
bMale patients (%)
cTwenty-seven patients were included for quantitative analysis; 14 patients for qualitative analysis